GRI Bio, Inc. (GRI)
NASDAQ: GRI · Real-Time Price · USD
2.360
-0.250 (-9.58%)
At close: Mar 20, 2026, 4:00 PM EDT
2.400
+0.040 (1.69%)
After-hours: Mar 20, 2026, 7:11 PM EDT
GRI Bio Employees
GRI Bio had 4 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,989,000
Market Cap
3.41M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 4 | 0 | - | 3 | 1 |
| Dec 31, 2024 | 4 | 0 | - | 3 | 1 |
| Dec 31, 2023 | 4 | 3 | 300.00% | 4 | 0 |
| Dec 31, 2022 | 1 | - | - | 1 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Aptevo Therapeutics | 37 |
| NuCana | 22 |
| Genprex | 13 |
| Revelation Biosciences | 9 |
| Indaptus Therapeutics | 7 |
| Galmed Pharmaceuticals | 6 |
| Oragenics | 5 |
| Matinas BioPharma Holdings | 3 |
GRI News
- 4 weeks ago - GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment - GlobeNewsWire
- 6 weeks ago - GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - GlobeNewsWire
- 6 weeks ago - GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights - GlobeNewsWire
- 7 weeks ago - GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF - GlobeNewsWire
- 2 months ago - GRI Bio Announces Reverse Stock Split - GlobeNewsWire
- 3 months ago - GRI Bio Announces Closing of $8.0 Million Public Offering - GlobeNewsWire
- 3 months ago - GRI Bio Announces Pricing of $8,000,000 Million Public Offering - GlobeNewsWire
- 3 months ago - GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewsWire